Corneal Cross-Linking

From EyeWiki

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.


Introduction

Corneal collagen cross-linking (CXL) is a photochemical treatment that increases the biomechanical stability of the corneal stroma using topical riboflavin and ultraviolet-A (UV-A) irradiation. Its principal objective is to slow or halt progressive corneal ectasia, particularly keratoconus and ectasia following refractive surgery; improvement in corneal curvature or vision may occur but is not guaranteed. CXL may be performed with epithelial removal (epithelium-off, or epi-off) or with preservation of the epithelial layer (epithelium-on, or epi-on). In the United States, FDA-approved epi-off treatment was introduced in 2016, and a distinct, oxygen-supplemented epi-on treatment was approved in October 2025.[1][2]

Background

Native enzymatic and nonenzymatic bonds between corneal extracellular-matrix components contribute to stromal resistance to deformation. Experimental work from Dresden established that UV-A irradiation of riboflavin-saturated corneal tissue could induce additional photochemical cross-links. Wollensak, Spoerl, and Seiler reported the first clinical results in progressive keratoconus in 2003.[3]

US regulatory approvals are specific to a drug/device regimen, not to all protocols described as CXL. In 2016, the FDA approved PHOTREXA VISCOUS/PHOTREXA with the KXL System for epi-off treatment of progressive keratoconus and post-refractive-surgery corneal ectasia. On October 17, 2025, the FDA approved EPIOXA HD/EPIOXA with the O2n System and Boost Goggles for epi-on treatment of keratoconus in patients aged 13 years or older. The latter indication does not include post-refractive-surgery ectasia.[1][2]

Basic Concepts

CXL combines topical riboflavin with controlled UV-A irradiation to promote photochemical stiffening of the corneal stroma. Tissue oxygen availability, riboflavin distribution, UV-A dose, exposure pattern, and corneal thickness all affect the treatment response.

Riboflavin

Riboflavin (vitamin B2) serves as the photosensitizer. It also absorbs UV-A radiation, providing some protection to deeper tissues when adequately distributed in the cornea. Because the epithelium is a barrier to stromal delivery, formulations and soaking techniques are protocol specific; epi-on and epi-off regimens cannot be treated as interchangeable. [2][1]

UV Light and Oxygen

UV-A radiation activates stromal riboflavin, which produces reactive oxygen species and photochemical cross-linking. The conventional Dresden epi-off protocol uses approximately 365–370 nm light at 3 mW/cm2 for 30 minutes (a total surface fluence of 5.4 J/cm2). This fluence is not a universal requirement: different approaches use other irradiances, pulsing schemes, oxygen concentrations, and total fluences. Although the Bunsen–Roscoe reciprocity principle relates irradiance and exposure time, equivalent total energy does not necessarily produce equivalent CXL efficacy because stromal oxygen availability and other kinetics differ. The FDA-approved EPIOXA epi-on regimen uses supplemental oxygen and pulsed UV-A irradiation at 30 mW/cm2 for 11 minutes 6 seconds (one second on and one second off), approximately 10 J/cm2 of delivered fluence.[2][1]

Photochemical Reaction

UV-A irradiation of riboflavin generates reactive oxygen species that induce chemical changes in stromal collagen and associated extracellular matrix. The reaction is particularly sensitive to oxygen availability at higher irradiances; an identical nominal energy dose does not guarantee an identical biomechanical response. Oxygen-supplemented and pulsed protocols seek to account for this constraint.[4]

Patient Selection

Indications and Assessment of Progression

The best-established indication for CXL is progressive keratoconus; epi-off CXL is also FDA-approved for corneal ectasia after refractive surgery. Other ectatic conditions, including pellucid marginal degeneration, may be treated in selected patients, but the evidence and regulatory indications differ. CXL is intended for ectasia stabilization, not as a substitute for spectacles, contact lenses, or other methods of visual rehabilitation.[1]

Progression assessment should integrate serial corneal tomography/topography, including Kmax, anterior and posterior surface change, pachymetric progression, and thinnest-point pachymetry, together with manifest refraction and corrected distance visual acuity. An isolated change in Kmax should be interpreted in the context of measurement repeatability. The 2026 second Global Consensus recommends CXL for definitive topographic or tomographic progression and consideration of treatment upon diagnosis in pediatric patients with confirmed keratoconus rather than requiring serial proof of progression.[5]

For US labeling, the PHOTREXA/KXL epi-off regimen has not established safety and efficacy in children younger than 14 years, whereas the EPIOXA/O2n epi-on regimen is indicated for keratoconus beginning at age 13 years. These thresholds describe the respective FDA product labels, not a prohibition on clinical CXL outside the labeled pediatric age range in other jurisdictions.[1][2]

Contraindications and Precautions

Treatment suitability depends on the selected protocol and its labeling. Active keratitis or clinically important ocular surface disease should be addressed before proceeding; severe scarring, poor wound healing, or inadequate stromal thickness may change the risk-benefit assessment. A prior episode of herpetic keratitis is a precaution because UV exposure and postoperative inflammation may trigger reactivation, but it should not be described as an absolute contraindication to every CXL regimen.[2]

For the FDA-approved EPIOXA regimen, the listed contraindications are hypersensitivity to benzalkonium chloride or other formulation ingredients and aphakia or pseudophakia without a UV-blocking intraocular lens. Its label recommends avoiding treatment during pregnancy and specifically warns against irradiating an eye if post-soak corneal thickness is below 325 µm. The FDA-approved PHOTREXA epi-off regimen requires at least 400 µm before irradiation, with appropriate riboflavin loading. These thickness criteria are not interchangeable.[2][1]

Surgical Technique

Treatment parameters should follow the specific protocol and, where applicable, the manufacturer's instructions for the approved drug/device combination. The following outlines the two US FDA-approved regimens; other protocols used internationally may differ.

Epithelium-off CXL: PHOTREXA with KXL System

  1. Apply topical anesthesia and debride approximately 9 mm of central corneal epithelium.
  2. Instill PHOTREXA VISCOUS (riboflavin 5'-phosphate ophthalmic solution 0.146% in 20% dextran) every two minutes for 30 minutes. Confirm riboflavin penetration by observing yellow anterior chamber flare.
  3. Measure corneal thickness by ultrasound pachymetry. When thickness is below 400 µm, the label directs administration of hypotonic PHOTREXA until at least 400 µm is achieved; do not irradiate below that threshold.
  4. Deliver 365 nm UV-A at 3 mW/cm2 for 30 continuous minutes with the KXL System, continuing PHOTREXA VISCOUS every two minutes during irradiation.
  5. Provide appropriate postoperative antibiotic, anti-inflammatory, analgesic, and epithelial-healing care, including a bandage contact lens as clinically indicated.[1]

The following video illustrates a conventional epi-off procedure, not the FDA-approved epi-on EPIOXA technique:

Epithelium-on CXL: EPIOXA with O2n System and Boost Goggles

The epithelium is not debrided. The following sequence is summarized from the FDA prescribing information and is specific to the EPIOXA platform:

  1. Apply topical anesthetic, insert a lid speculum, and gently clear the mucin layer using a cellulose spear soaked with EPIOXA HD, without removing the epithelium.
  2. Instill two drops of EPIOXA HD 0.239% every 60 seconds for four minutes; then instill two drops of EPIOXA 0.177% every 30 seconds for six minutes.
  3. Rinse the ocular surface with approximately 5 mL of balanced salt solution and perform ultrasound pachymetry. Do not irradiate if corneal thickness is below 325 µm.
  4. Apply the Boost Goggles and supplemental oxygen; use the O2n System to deliver pulsed 365 nm UV-A at 30 mW/cm2 for 11 minutes 6 seconds, alternating one second on and one second off.
  5. Maintain corneal hydration with balanced salt solution during irradiation, stop oxygen and remove the goggles and speculum afterward, and apply a bandage contact lens.[2]

Both regimens require clinical follow-up. The shorter epithelial recovery anticipated with epi-on treatment does not eliminate the possibility of epithelial defects, haze, inflammation, or infection.

Variations in Surgical Technique

Riboflavin

Epithelium-off versus epithelium-on delivery

  • Epi-off: Epithelial debridement permits more consistent stromal riboflavin penetration and has the longest body of comparative and long-term evidence for preventing ectatic progression. Its disadvantages include postoperative discomfort, epithelial healing time, and epithelial-related infection risk.
  • Epi-on: Preserving the epithelium may lessen early discomfort and epithelial complications, but also creates barriers to riboflavin diffusion, oxygen availability, and UV-A transmission. Historical transepithelial methods vary substantially in their efficacy; they should not be pooled indiscriminately with newer oxygen-supplemented methods.
  • Optimized epi-on: Newer strategies include penetration-enhanced riboflavin formulations, iontophoresis, supplemental oxygen, pulsed irradiation, and spatially customized UV-A delivery. The FDA-approved EPIOXA/O2n/Boost Goggles protocol is one particular combination and has shown efficacy versus sham treatment; it has not established noninferiority to FDA-approved epi-off CXL in a direct head-to-head pivotal trial.[2][6]

A small 2024 randomized fellow-eye trial involving 32 patients found similar mean Kmax flattening at 24 months with customized, high-oxygen epi-on and customized epi-off regimens; these results are protocol-specific and are not proof that all epi-on approaches match standard epi-off CXL.[7]

Osmolarity and thin corneas

Hypo-osmolar riboflavin has been used to induce stromal swelling before epi-off irradiation in thin corneas. However, swelling can be transient, and safety depends on actual intraoperative pachymetry and the full irradiation protocol. In the FDA-approved PHOTREXA/KXL regimen, irradiation is not performed unless the post-soak thickness is at least 400 µm. In the EPIOXA/O2n epi-on regimen, the corresponding labeled minimum is 325 µm.[1][2]

The ELZA-sub400 approach uses individualized UV-A exposure based on stromal thickness rather than attempting to reach a universal 400 µm value by swelling. In a retrospective series of 39 eyes with stromal thicknesses of 214–398 µm, an October 2026 five-year follow-up report found no endothelial decompensation, although only 18 eyes completed the full five-year follow-up. This specialized protocol should not be extrapolated to routine CXL or assumed to meet US product labeling.[8][9]

UV Exposure

Treatment time and accelerated CXL

Accelerated epi-off protocols increase irradiance to shorten exposure (for example, 9 mW/cm2 for 10 minutes or 18 mW/cm2 for five minutes, each nominally delivering 5.4 J/cm2). The photochemical response cannot be inferred from total fluence alone because oxygen replenishment and riboflavin kinetics matter. Clinical studies have demonstrated stabilization with multiple accelerated techniques, although long-term comparative results vary. The 2026 global consensus identified 9 mW/cm2 for 10 minutes as the most commonly used accelerated epi-off protocol among respondents; choice should consider patient and corneal characteristics.[5]

Higher-fluence pulsed epi-on CXL, such as the FDA-approved oxygen-supplemented EPIOXA protocol, is a different regimen and should not be described simply as an accelerated Dresden protocol.[2]

Positioning

Conventional CXL is generally performed with the patient supine. Slit-lamp-based and upright approaches have been investigated, but device geometry, exposure uniformity, eye movement, and intraoperative hydration must be accounted for in selecting an alternate position.[10]

Effects, Safety, and Follow-up

CXL primarily increases anterior stromal biomechanical stability. Some treated eyes subsequently show reduced Kmax or improved corrected visual acuity, but the principal endpoint is stabilization and the magnitude and durability of flattening vary by protocol and patient. After epi-off treatment, re-epithelialization commonly takes several days. Transient pain, photophobia, haze, epithelial defects, sterile infiltrates, and infection can occur; severe scarring or endothelial injury is uncommon when appropriate techniques and thickness limits are respected. Epi-on treatment generally avoids a large debridement-related epithelial defect but does not eliminate ocular surface adverse effects.[1][2]

A 2026 retrospective US study of 243 eyes treated with epi-off CXL found significant visual improvements in the cohort, although follow-up attrition limits interpretation of five-year outcomes.[11]

Postoperative surveillance should include corrected visual acuity, refraction, corneal tomography/topography, and pachymetry using comparable instruments and acquisition quality. A transient postoperative change in Kmax should not alone establish treatment failure. Confirmed repeat progression warrants reassessment of eye rubbing, atopy, ocular surface disease, and treatment adequacy. Repeat CXL can be appropriate; the 2026 global consensus favors epi-off retreatment when keratoconus progresses after an epi-on procedure.[5]

Cross-linking Applications

Keratoconus

CXL is the principal intervention to reduce the risk of progression in keratoconus, particularly in younger patients and eyes with documented corneal shape change. The 2026 global consensus recommends treating definite progression and considering CXL at diagnosis in children with topographically or tomographically confirmed disease. Epi-off CXL remains preferred for rapidly progressive or advanced cases; epi-on treatment may be considered for selected milder or lower-risk cases, taking account of the particular device and protocol. Avoidance of eye rubbing and control of allergic eye disease are important adjuncts but should not delay indicated CXL.[5]

CXL does not by itself replace visual rehabilitation. Specialty contact lenses (including scleral lenses), intracorneal ring segments, corneal allogenic intrastromal ring segments, and selected surface-ablation strategies may be combined or staged with CXL to improve optical quality. Surface ablation carries tissue-removal considerations and requires careful individualized assessment.[5]

Pellucid Marginal Degeneration

Pellucid marginal degeneration is an ectatic condition typically involving inferior peripheral thinning. Decentered or customized CXL has been reported in selected cases to slow progression and delay corneal transplantation. Evidence is smaller and less robust than that for keratoconus, and neither US-approved CXL regimen has a specific FDA indication for pellucid marginal degeneration.[12]

Ectasia Following Refractive Surgery

For progressive corneal ectasia after LASIK or other refractive procedures, CXL may stabilize corneal shape and sometimes improve optical quality. The US FDA-approved PHOTREXA/KXL epi-off regimen includes an indication for post-refractive-surgery ectasia, whereas the EPIOXA/O2n epi-on indication is limited to keratoconus. Combining CXL with topography-guided surface ablation (often termed CXL Plus or the Athens protocol) has been described for visual rehabilitation but requires individualized assessment of remaining tissue and ectasia risk.[1][2][13]

Photo-activated Chromophore for Infectious Keratitis (PACK-CXL)

PACK-CXL is being investigated as an adjunctive treatment for infectious keratitis and corneal melting, based on possible antimicrobial and stromal-stabilizing effects. Evidence varies by organism and clinical presentation. It should not replace appropriate microbiologic investigation, topical antimicrobials, or emergency tectonic management when indicated.[14]

Bullous Keratopathy

CXL has been studied as a palliative intervention for symptomatic endothelial decompensation, but reported improvement in edema and vision has generally been transient. It is not an established substitute for definitive endothelial or penetrating keratoplasty when indicated.[15]

Studies and Trials

The sections below summarize seminal trials of conventional epi-off cross-linking. They are preserved for historical context, including their original follow-up limitations and crossover designs. The subsequent subsection reviews newer randomized epi-on evidence and small optimized-protocol comparisons. Early statements in historical trial reports concerning limited evidence should be read in their publication-era context rather than as the current state of evidence.

Dresden Long-term Keratoconus Study

Raiskup-Wolf and colleagues reported outcomes from 480 treated eyes of 272 keratoconus patients. At least six months of data were available in 241 eyes, but only 33 eyes had three or more years of follow-up. Mean keratometry decreased by approximately 2.68 D at one year; 87% of the smaller three-year cohort was stable or improved. Long-term attrition and nonrandomized design limit precision.[16]

Siena Eye Cross Study

The Siena series enrolled 363 progressive keratoconus eyes. In the 44 eyes with at least four years of follow-up, investigators reported reductions in mean keratometry of approximately 2.26 D from baseline. The observational design and substantial attrition restrict the strength of conclusions about durable population-wide benefit.[17]

Australian Randomized Controlled Trial

Wittig-Silva and colleagues randomized eyes with progressive keratoconus to conventional epi-off CXL or observation. The three-year analysis demonstrated mean flattening of approximately 1.03 D in treated eyes versus steepening of approximately 1.75 D in controls. Interpretation requires attention to control-eye crossovers, loss to follow-up, and the fact that control eyes were not sham treated.[18]

United States Multicenter Epi-off Registration Trials

The US registration studies of conventional epi-off CXL enrolled 204 eyes with keratoconus and 178 eyes with ectasia after refractive surgery. In treated eyes at 12 months, Kmax declined by about 1.6 D and 0.7 D, respectively; sham-control crossover after three months complicates longer-term comparisons. The randomized results contributed to the evidence underpinning the FDA's initial 2016 approval.[19][20]

FDA-approved epithelium-on CXL: Phase III randomized trials

Two pivotal randomized, sham/vehicle-controlled studies (NCT03442751 and NCT05759559) evaluated the EPIOXA/O2n oxygen-supplemented epi-on protocol in keratoconus, encompassing 592 randomized eyes from 409 patients. Study 1 randomized 280 eyes; 189 received active treatment and 90 received sham treatment, with a prespecified six-month primary endpoint. The between-group adjusted difference in Kmax change at six months was approximately -1.0 D (95% CI -1.5 to -0.4; P < 0.01). Study 2 enrolled 312 eyes (200 active and 112 sham); at the 12-month primary endpoint, mean Kmax changed -0.5 D with treatment and +0.4 D with sham, corresponding to a treatment effect of -1.0 D (95% CI -1.3 to -0.6; P < 0.01). These data supported the 2025 FDA approval.[2]

The second pivotal trial was published in 2026 as a peer-reviewed Phase III report. It demonstrated efficacy versus sham treatment; the studies did not directly compare EPIOXA with the FDA-approved PHOTREXA epi-off protocol. Accordingly, efficacy against a sham control should not be interpreted as noninferiority to epi-off CXL.[6]

In October 2026, the manufacturer reported three-year extension results from 38 study eyes, including mean Kmax flattening of 1.9 D from baseline in the extension cohort. These findings are preliminary sponsor-reported results from a small, selected follow-up group, rather than a completed peer-reviewed head-to-head comparison, and should be interpreted cautiously.[21]

Additional comparative evidence for optimized epi-on CXL

A 2024 randomized fellow-eye study of 32 patients compared customized epi-on CXL with supplemental oxygen against customized epi-off CXL in room air. At 24 months, mean Kmax flattening was approximately 1.74 D and 1.72 D, respectively, with less first-week discomfort in epi-on eyes. The trial is informative for its specific customized regimens but is too small and methodologically distinct to establish equivalence between all epi-on and epi-off protocols.[7]

Complications

Potential complications differ by technique and include postoperative pain and photophobia; epithelial defects or delayed healing; transient stromal haze, sterile infiltrates, or scarring; microbial or herpetic keratitis; endothelial injury if safety limits are violated; and continued ectatic progression despite treatment. Epi-off CXL requires particular attention to epithelial healing and contact lens-associated infection risk. Patients with advanced corneal thinning, ocular allergy, blepharitis, or other active ocular surface disease require careful optimization and counseling.[1][22]

In the two EPIOXA registration trials, 389 epi-on CXL-treated eyes contributed to the FDA safety analysis. Conjunctival hyperemia occurred in 31%; other reported adverse reactions included haze, punctate keratitis, photophobia, discomfort, epithelial defects, dry eye, and reduced visual acuity. Clinical-trial adverse-event percentages should not be compared directly across different drug/device programs or assumed to predict real-world rates.[2]

Special Situations

Pediatric Keratoconus

Keratoconus can progress rapidly in children and adolescents. The 2026 second Global Consensus recommends considering CXL as soon as keratoconus is confirmed by corneal imaging in pediatric patients, without necessarily waiting for documented progression. Epi-off CXL is generally preferred for documented progression; observation or selected epi-on/epi-off treatment may be discussed where progression is not yet shown. Children require prolonged postoperative monitoring because repeat progression can occur years later.[5]

For US regulatory purposes, the EPIOXA epi-on formulation/device combination is indicated beginning at age 13, whereas safety and efficacy of PHOTREXA epi-off CXL have not been established by the FDA below age 14. These are product-specific labeling distinctions and should not be conflated with international recommendations.[2][1]

Thin Cornea

The original Dresden protocol requires a sufficiently thick cornea to limit endothelial UV-A exposure, and the FDA-approved epi-off PHOTREXA/KXL labeling specifies a minimum of 400 µm at irradiation. Modified approaches for thinner corneas include hypo-osmolar swelling, contact lens-assisted CXL, and thickness-adjusted UV-A dosing (for example, the ELZA-sub400 protocol). Each method has different assumptions, evidence, and safety constraints; a report of efficacy in an ultrathin cornea should not be interpreted as authorization to use an unmodified conventional protocol at that thickness.[1][9]

The FDA-approved EPIOXA oxygen-supplemented epi-on regimen instead requires at least 325 µm by ultrasound pachymetry after riboflavin application. The separate thickness thresholds reflect distinct approved protocols and cannot be freely substituted.[2]

Corneal Ectasia in Pregnancy

Pregnancy-related hormonal and biomechanical changes can coincide with ectatic progression; patients with known keratoconus should be monitored according to their individual risk. Both US-approved CXL prescribing information sets state that treatment should not be performed during pregnancy because reproductive safety has not been established. Decisions about monitoring and post-partum treatment should be individualized. Evidence is insufficient to recommend categorical avoidance of hormonal contraception solely because of keratoconus.[2][1]

Advances in CXL

Pulsed CXL and Oxygen Supplementation

Pulsed UV-A irradiation permits intervals for stromal oxygen replenishment and is especially relevant to higher-irradiance protocols. Oxygen enrichment is incorporated into several contemporary epi-on approaches. The FDA-approved EPIOXA/O2n regimen combines supplemental oxygen with one-second-on/one-second-off UV-A pulses; the specific parameters and evidence should not be generalized to other devices or formulations.[2]

Adapted Fluence and Customized CXL

Thickness-adjusted and topography-guided UV-A patterns seek to tailor treatment to local corneal shape or stromal reserve. The ELZA-sub400 protocol, for example, adjusts exposure for thinner corneas and has encouraging nonrandomized data, including a small 2026 five-year follow-up report; however, it remains protocol-specific. Customized, oxygen-enhanced epi-on approaches have also shown promising multi-year results in small studies. Further comparative and long-term evidence is needed before such findings can be generalized across CXL platforms.[9][7]

LASIK Xtra

LASIK Xtra combines laser refractive surgery with an adjunctive, typically modified CXL exposure intended to reduce biomechanical destabilization. Although studies have evaluated refractive stability, evidence is insufficient to establish routine prophylactic CXL as a reliable substitute for appropriate ectasia-risk screening, adequate residual stromal thickness, and conservative refractive surgical planning. This approach is not equivalent to FDA-approved therapeutic CXL for progressive keratoconus or post-refractive ectasia.

Photorefractive Intrastromal CXL

Spatially customized or higher-fluence CXL has been explored for refractive flattening in low myopia and irregular corneas. These investigational approaches should be distinguished from CXL intended to treat progressive corneal ectasia; they are not established routine refractive substitutes for laser vision correction.

Scleral Cross-Linking for Axial Myopia

Scleral cross-linking aims to alter the biomechanical properties of the posterior eye wall in progressive axial myopia. Although experimental studies have explored this concept, clinical safety, dose delivery, and sustained efficacy remain investigational.

Other Investigational CXL Approaches

Alternative photosensitizers, such as rose bengal, chemical cross-linkers, contact lens-assisted procedures for thin corneas, and intrastromal riboflavin delivery have been reported. Each differs substantially in mechanism, energy delivery, potential adverse effects, and evidence base; none should be assumed equivalent to an FDA-approved CXL treatment regimen.

Emerging Monitoring and Theranostic Approaches

Current research includes patient-specific UV-A dosing, real-time evaluation of riboflavin distribution and oxygen availability, biomechanical imaging, and algorithm-assisted treatment planning. These techniques may ultimately allow more individualized CXL, particularly in thin or irregular corneas, but robust prospective clinical validation is needed before AI-guided dosimetry or intraprocedural measurement systems can be considered established standards of care.[5]

Summary

Corneal collagen cross-linking is an established intervention for limiting the progression of keratoconus and related ectatic disease. Conventional epi-off CXL retains the most extensive long-term evidence and an FDA-approved indication for post-refractive ectasia. Since October 2025, oxygen-supplemented epi-on CXL with EPIOXA/O2n has also been FDA-approved for keratoconus in patients aged 13 years and older, with Phase III efficacy demonstrated against sham treatment. The two approved platforms differ in indications, drug formulations, riboflavin delivery, thickness requirements, irradiance, and postoperative recovery. Robust head-to-head evidence for noninferiority of the FDA-approved epi-on treatment versus standard epi-off CXL remains unavailable.[1][2][6]

Treatment selection should be individualized according to age, progression, severity, corneal thickness, ocular surface status, patient expectations, and the evidence for the specific protocol. Continued tomography and visual follow-up remain important after either approach.[5]

Summary of corneal collagen cross-linking. Original figure courtesy of Dr. Amanda Mohanan Earatt.

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 US Food and Drug Administration. PHOTREXA VISCOUS/PHOTREXA prescribing information, revised February 2025. FDA label.
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 US Food and Drug Administration. EPIOXA HD/EPIOXA prescribing information, revised October 2025. FDA label.
  3. ↑ Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135(5):620-627.
  4. ↑ Subasinghe SK, Ogbuehi KC, Dias GJ. Current perspectives on corneal collagen crosslinking (CXL). Graefes Arch Clin Exp Ophthalmol. 2018;256:1363-1384. doi:10.1007/s00417-018-3966-0.
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Gomes JAP, Hafezi F, Ambrósio R Jr, et al. Global Consensus on Keratoconus and Ectatic Diseases—Edition 2. Cornea. 2026;45(7):888-908. doi:10.1097/ICO.0000000000004170.
  6. ↑ 6.0 6.1 6.2 Beckman KA, Parkhurst GD, Lee JH, et al. Randomized, Controlled Study to Evaluate the Safety and Efficacy of Oxygen-Enriched Epithelium-On Corneal Cross-Linking for the Treatment of Keratoconus. Ophthalmol Ther. 2026;15:1463-1484. doi:10.1007/s40123-026-01364-7.
  7. ↑ 7.0 7.1 7.2 Elving S, Fredriksson A, Beckman Rehnman J, Behndig A. Randomized clinical trial comparing customized corneal crosslinking: epi-on in high oxygen and epi-off in room air for keratoconus. J Cataract Refract Surg. 2024;50(7):746-753. doi:10.1097/j.jcrs.0000000000001442.
  8. ↑ Torres-Netto EA, Kling S, Akcan RE, et al. Five-Year Follow-up of the ELZA-sub400 Protocol: Individualized Corneal Cross-linking With Riboflavin and UV-A in Ultrathin Keratoconic Corneas. J Refract Surg. 2026;42(10):e416-e424. doi:10.3928/1081597X-20260728-01.
  9. ↑ 9.0 9.1 9.2 Hafezi F, Hillen M, Kling S, et al. Cross-linking treatment of ultrathin corneas: the ELZA-sub400 protocol. Ophthalmologie. 2026;123:605-610. doi:10.1007/s00347-026-02467-z.
  10. ↑ Salmon B, et al. CXL at the slit lamp: no clinically relevant changes in corneal riboflavin distribution during upright UV irradiation. J Refract Surg. 2017;33(4):281.
  11. ↑ Chen KM, Wungcharoen T, Zhao C, Myung D, Manche EE. Long-term outcomes of corneal crosslinking for keratoconus across pediatric, adolescent, and adult populations in a diverse U.S. population. J Cataract Refract Surg. 2026;52(9):872-878. doi:10.1097/j.jcrs.0000000000001932.
  12. ↑ Raiskup F, Spoerl E. Corneal crosslinking with riboflavin and ultraviolet A. Part II. Clinical indications and results. Ocul Surf. 2013;11:93-108. doi:10.1016/j.jtos.2013.01.003.
  13. ↑ Hersh PS, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. Ophthalmology. 2017;124:1475-1484. doi:10.1016/j.ophtha.2017.05.036.
  14. ↑ Sachdev GS, Sachdev M. Recent advances in corneal collagen cross-linking. Indian J Ophthalmol. 2017;65:787. doi:10.4103/ijo.IJO_648_17.
  15. ↑ Raiskup F, Spoerl E. Corneal crosslinking with riboflavin and ultraviolet A. Part II. Clinical indications and results. Ocul Surf. 2013;11:93-108. doi:10.1016/j.jtos.2013.01.003.
  16. ↑ Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008;34:796-801.
  17. ↑ Caporossi A, et al. Long-term results of riboflavin ultraviolet A corneal collagen cross-linking for keratoconus in Italy: the Siena Eye Cross Study. Am J Ophthalmol. 2010;149:585-593.
  18. ↑ Wittig-Silva C, Chan E, Islam FM, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. Ophthalmology. 2014;121:812-821. doi:10.1016/j.ophtha.2013.10.028.
  19. ↑ Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. Ophthalmology. 2017;124:1259-1270. doi:10.1016/j.ophtha.2017.03.052.
  20. ↑ Hersh PS, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. Ophthalmology. 2017;124:1475-1484. doi:10.1016/j.ophtha.2017.05.036.
  21. ↑ Glaukos Corporation. Three-year EPIOXA extension study topline announcement. October 7, 2026.
  22. ↑ Korkmaz I, Palamar M. Complications of corneal crosslinking: What can go wrong? Surv Ophthalmol. Published online February 24, 2026. doi:10.1016/j.survophthal.2026.02.009.